Effectiveness and Treatment Compliance of Salmeterol-Fluticasone Easyhaler ® Among Patients with Asthma, COPD, or Asthma-COPD Overlap Syndrome: Real-World Study Findings.

Autor: Tamási L; Department of Pulmonology, Faculty of Medicine, Semmelweis University, Tömő utca 25-29, 1083, Budapest, Hungary. tamasi.lilla@med.semmelweis-univ.hu., Bartha A; Siófok Hospital and Outpatient Clinic of Pulmonology, Siófok, Hungary., Ferencz A; Ferenc Toldy Hospital and Outpatient Clinic of Pulmonology, Cegléd, Hungary., Tímár M; Hungarian Army Medical Center, Budapest, Hungary., Vahteristo M; Orion Corporation, Espoo, Finland., Takala A; Orion Corporation, Espoo, Finland., Müller V; Department of Pulmonology, Faculty of Medicine, Semmelweis University, Tömő utca 25-29, 1083, Budapest, Hungary.
Jazyk: angličtina
Zdroj: Pulmonary therapy [Pulm Ther] 2022 Dec; Vol. 8 (4), pp. 369-384. Date of Electronic Publication: 2022 Nov 01.
DOI: 10.1007/s41030-022-00201-z
Abstrakt: Introduction: For inhalation therapies to be effective, it is crucial that patients manage inhaler use correctly in their everyday life and achieve treatment compliance. We investigated the effectiveness of the salmeterol-fluticasone propionate Easyhaler ® (SF EH) device-metered dry powder inhaler in a real-world setting in Hungary among adult patients with asthma, chronic obstructive pulmonary disease (COPD), or asthma-COPD overlap syndrome (ACO).
Methods: A prospective, open-label, multicenter, noninterventional, investigator-sponsored study was conducted in outpatient pneumonology centers. Eligible patients were aged ≥ 18 years with either a new diagnosis of asthma, COPD, or ACO, or whose disease was not controlled with preexisting medication. Data were collected at baseline and 12 + 4 weeks, including the asthma control test (ACT), COPD assessment test (CAT), spirometry parameters [including forced expiratory volume for 1 s (FEV 1 )], and physician- and patient-reported outcomes.
Results: Five hundred sixteen patients were recruited from 103 centers: 376 with asthma; 104 with COPD; and 36 with ACO. At week 12, there were significant improvements from baseline in both mean ACT score in patients with asthma (14.4 ± 4.2 versus 21.4 ± 2.8; P < 0.001) and mean CAT score in patients with COPD (24.0 ± 6.1 versus 16.0 ± 5.8; P < 0.001). Significant improvement was observed when the switch from the most frequently used previous inhalers was analyzed separately. Mean FEV 1 improved from 76.0% ± 17.2 to 84.7% ± 16.1 (P < 0.001) and from 53.8% ± 15.0 to 59.9% ± 15.0 (P < 0.001) in patients with asthma or COPD, respectively. The study demonstrated improved physician-rated overall treatment compliance and patient preference for the SF EH over 3 months use compared with previous inhaler treatment, with patients effectively adopting the SF EH into everyday life.
Conclusions: Treatment with SF EH significantly improved patients' lung function parameters and disease control.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje